Scilex Holding (SCLXW) Operating Income (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Operating Income of -$32.2 million in Q1 2026, up 71.04% quarter-over-quarter from -$111.1 million in Q4 2025, and down 15.31% on a YoY basis from -$38.0 million in Q1 2025.
Scilex Holding (SCLXW) Operating Income (2020 - 2026) Analysis & Trends
Scilex Holding's Operating Income history runs 7 years deep, the most recent figure standing at -$32.2 million for Q1 2026.
- In Q1 2026, Operating Income fell 15.31% year-over-year to -$32.2 million; the TTM figure through Mar 2026 stood at -$350.3 million (down 281.5% YoY), while the FY2025 annual figure was -$346.0 million, down 314.9% from the prior year.
- Operating Income was -$32.2 million for Q1 2026 at Scilex Holding, up from -$111.1 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$8.8 million in Q1 2022 to a low of -$186.5 million in Q3 2025.
- Historically, Operating Income has averaged -$36.3 million across 5 years, with a median of -$20.5 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Operating Income slumped 6563.76% in 2022, then jumped 48.67% in 2024.
- A 5-year view of Operating Income shows it stood at -$19.7 million in 2022, then rose by 7.1% to -$18.3 million in 2023, then sank by 54.74% to -$28.4 million in 2024, then plunged by 291.47% to -$111.1 million in 2025, then soared by 71.04% to -$32.2 million in 2026.
- The last three Operating Income figures came in at -$32.2 million (Q1 2026), -$111.1 million (Q4 2025), and -$186.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.09 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -182.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -32.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.17 Mn |
| Dec 31, 2025 | -111.09 Mn |
| Sep 30, 2025 | -186.51 Mn |
| Jun 30, 2025 | -20.51 Mn |
| Mar 31, 2025 | -27.90 Mn |
| Dec 31, 2024 | -28.38 Mn |
| Sep 30, 2024 | -19.92 Mn |
| Jun 30, 2024 | -15.62 Mn |
| Mar 31, 2024 | -19.48 Mn |
| Dec 31, 2023 | -18.34 Mn |
| Sep 30, 2023 | -38.81 Mn |
| Jun 30, 2023 | -22.81 Mn |
| Mar 31, 2023 | -25.47 Mn |
| Dec 31, 2022 | -19.74 Mn |
| Sep 30, 2022 | -10.62 Mn |
| Jun 30, 2022 | -11.47 Mn |
| Mar 31, 2022 | -8.81 Mn |
| Dec 31, 2021 | -35.22 Mn |
| Sep 30, 2021 | -283,346.00 |
| Jun 30, 2021 | -172,140.00 |